Evidence map›Paper›PMID 30610611›Full record

ArticleMolecular neurobiology2019

Adenosine A

Ester Aso, Víctor Fernández-Dueñas, Marc López-Cano, Jaume Taura, Masahiko Watanabe, Isidre Ferrer, Rafael Luján, Francisco Ciruela

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Involvement of Adenosine ABrain and behavior · 2026
    Article
  4. Article
  5. Review
  6. Cannabidiol negatively modulates adenosine AActa neuropsychiatrica · 2024
    Article
  7. Article
  8. Neuronal and astrocytic CB1R signaling differentially modulates goal-directed behavior and working memory by distinct temporal mechanisms.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023
    Article
  9. Review
  10. Adenosine ABiomolecules · 2023
    Article
  11. Review
  12. Striatopallidal adenosine ANeuropharmacology · 2023
    Review
  13. THC and CBD: Villain versus Hero? Insights into Adolescent Exposure.International journal of molecular sciences · 2023
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Negative allosteric modulation of CBPharmacological research · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Ester AsoUnitat de Farmacologia, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la Salut, IDIBELL-Universitat de Barcelona, C/Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Spain.
Víctor Fernández-DueñasUnitat de Farmacologia, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la Salut, IDIBELL-Universitat de Barcelona, C/Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Spain.
Marc López-CanoUnitat de Farmacologia, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la Salut, IDIBELL-Universitat de Barcelona, C/Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Spain.
Jaume TauraUnitat de Farmacologia, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la Salut, IDIBELL-Universitat de Barcelona, C/Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Spain.
Masahiko WatanabeDepartment of Anatomy, Hokkaido University School of Medicine, Sapporo, Japan.
Isidre FerrerUniversitat de Barcelona, Institut de Neurociències, Barcelona, Spain.
Rafael LujánSynaptic Structure Laboratory, Instituto de Investigación en Discapacidades Neurológicas (IDINE), Departamento de Ciencias Médicas, Facultad de Medicina, Universidad Castilla-La Mancha, Campus Biosanitario, Albacete, Spain.
Francisco CiruelaUnitat de Farmacologia, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la Salut, IDIBELL-Universitat de Barcelona, C/Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Spain. fciruela@ub.edu.ORCID http://orcid.org/0000-0003-0832-3739
Institut d'Investigació Biomédica de Bellvitge · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESDepartament de Salut · ESHokkaido University · JPUniversity of Castilla-La Mancha · ES

Funding

Fonds Wetenschappelijk Onderzoek SBO-140028Fundació la Marató de TV3 Grant 20152031Instituto de Salud Carlos III PI14/00757Instituto de Salud Carlos III PIE14/00034Ministerio de Economía, Industria y Competitividad, Gobierno de España BFU2015-63769-RMinisterio de Economía, Industria y Competitividad, Gobierno de España SAF2017-87349-R
6 · The paper itself

Abstract

At present, clinical interest in the plant-derived cannabinoid compound cannabidiol (CBD) is rising exponentially, since it displays multiple therapeutic properties. In addition, CBD can counteract the undesirable effects of the psychoactive cannabinoid Δ

Indexed as

Protein MultimerizationAnimalsCannabidiolCognitive DysfunctionDronabinolHippocampusLocomotionMaleMice, Inbred C57BLPresynaptic TerminalsReceptor, Adenosine A2AReceptor, Cannabinoid, CB1CannabidiolDronabinolReceptor, Adenosine A2AReceptor, Cannabinoid, CB1Adenosine 2A receptorCannabidiolCannabinoid 1 receptorCannabisMemoryΔ9-Tetrahydrocannabinol

Identifiers

PMID30610611
OpenAlexW2908424569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.